Introduction
Psoriasis affects approximately 2–3% of the global population and represents a chronic, immune-mediated inflammatory disorder. The disease imposes a substantial burden on patients, manifesting with scaly cutaneous plaques and, in many individuals, painful psoriatic arthritis that significantly impairs mobility. Although historically regarded as a primarily dermatological condition, psoriasis is now recognized as a systemic disease driven by complex inflammatory pathways. These mechanisms contribute to immune dysregulation and are associated with a wide range of comorbidities, including cardiovascular disease, metabolic syndrome, and psychiatric disorders such as depression and anxiety [1].
The psychosocial effects of psoriasis are profound, with numerous studies reporting a significant reduction in patients’ quality of life due to physical pain, psychological distress, and social stigma. The principal aim of this paper is to examine how pain, stress, and depression converge to create a complex burden for individuals living with psoriasis. Pain in psoriasis is multifaceted, frequently manifesting as both cutaneous discomfort and arthritic pain. These symptoms detrimentally affect daily functioning and further exacerbate co-occurring psychological difficulties.
Increasing attention has been directed toward the relationship between psoriasis and depression, with research highlighting a bidirectional association involving not only psychosocial stressors but also shared inflammatory pathways. This paper seeks to deepen the understanding of inflammation as a common mechanism influencing both dermatologic and mood symptoms by elucidating the roles of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, which are implicated in the pathophysiology of both psoriasis and depressive disorders. Stress, a well established precipitating factor for the onset and severity of psoriasis, interacts dynamically with these symptoms, perpetuating a cycle of exacerbation that necessitates targeted intervention.
This study aims to clarify the mechanisms linking pain, stress, and depression in psoriasis through a comprehensive review of existing literature and to highlight the potential benefits of integrative, anti-inflammatory therapeutic strategies. Current evidence demonstrates that comprehensive care approaches addressing both the physical and psychological components of psoriasis offer more holistic management and contribute to sustained improvements in patients’ quality of life.
THE INTERPLAY OF PAIN, DEPRESSION, AND STRESS IN PSORIASIS AND ITS IMPACT ON QUALITY OF LIFE
Psoriasis is a complex systemic inflammatory disease, affecting both physical and psychological well-being, with the ability to impair patients’ daily activities and significantly lowering the quality of life.
In addition to its physical effects, psoriasis is linked to substantial psychological difficulties, particularly in the areas of pain, depression, and stress. These factors interact in a complex cycle that further reduces quality of life.
Pain is a common symptom of psoriasis, experienced by approximately 40% of patients, with an average reported intensity of 4.4 on a 10-point scale. The pain associated with psoriasis can manifest as burning, stinging, or tenderness sensations and is attributed to both cutaneous lesions and joint inflammation in cases of psoriatic arthritis. The pain is of a multifaceted nature, involving both nociceptive and neuropathic elements. The challenge of neuropathic pain is compounded by the fact that it results from dysregulated nerve pathways, which are themselves exacerbated by the persistent inflammatory state that is associated with psoriasis. The complexity of pain types presents a challenge for traditional dermatological pain assessments, which primarily evaluate itch and scaling but do not fully capture the chronic pain experienced by many patients. Pain is a very common symptom in patients who suffer from psoriatic arthritis, affecting up to 48% of them. Most prevalent affected joints are those located in fingers, spine and also knee joints, which can further reduce patients’ physical activity and independence [2]. The standard treatments for patients with psoriasis-related pain are non-steroidal anti-inflammatory drugs (NSAIDs) and biological agents that target specific cytokines, such as TNF-α. Unfortunately, the complexity of psoriatic pain often proves that standard treatments are not sufficient, and some patients may experience sensory abnormalities, such as excessive responses to minor physical contact. Pain remains an important factor which affects not only physical discomfort but also intensifies psychological distress, forcing suffering patients to rely strongly on medical interventions.
Depression is one of the most prevalent psychological comorbidities associated with psoriasis, affecting 20–62% of patients depending on disease severity. The relationship between psoriasis and depression is not solely a consequence of the visible and often painful nature of the disease; it also has a strong biological basis. Psoriasis is a chronic systemic inflammatory condition characterized by elevated levels of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β. These cytokines are capable of crossing the blood-brain barrier, where they disrupt neurochemical pathways involved in mood regulation, particularly serotonergic signaling, which plays a central role in the pathophysiology of depression. Through this mechanism, systemic inflammation in psoriasis may directly contribute to the development and maintenance of depressive symptoms [3].
In addition to that, psoriasis’ impact on psychological well-being is frequently increased because of chronic and relapsing exacerbations of the disease. Up to 80% of patients report that they feel ashamed, isolated and have lower capacity to be socially active, including work, contributing to further lower life satisfaction [4].
Furthermore, both inflammation and stress associated with depression seem to exacerbate each other, causing worsening of skin condition and psychological deterioration.
It has been proposed that anti-inflammatory treatments, particularly TNF-α inhibitors, may alleviate depressive symptoms independently of their effect on skin symptoms. This would support the hypothesis that inflammation is a shared mechanism in both psoriasis and depression [5].
It has been established that stress is both a trigger and a consequence of psoriasis. Indeed, it has been reported that stress is a significant factor in up to 88% of flare-ups among patients. The activation of the hypothalamic–pituitary–adrenal (HPA) axis in response to stress leads to an increase in the production of glucocorticoids and catecholamines, which in turn promote the inflammatory process in psoriatic lesions. The dysregulation of the HPA axis persists in the context of chronic stress, intensifying cutaneous inflammation and precipitating episodes of pruritus and flare-ups. Furthermore, elevated levels of psychological stress have been demonstrated to enhance inflammatory markers such as TNF-α, thereby establishing a direct correlation between stress and both the exacerbation of cutaneous symptoms and the onset of depressive symptoms [6]. It is frequently reported by patients that stress serves to exacerbate both the visible symptoms and the psychological impact of the disease, particularly when lesions are located in areas that are visible to others, such as the face and hands. Women who value their appearance are more susceptible to stress-related exacerbations of psoriasis and depressive symptoms, which proves the gendered aspects of psoriasis distress [7].
Psoriasis-related social stigma and fear of negative judgement often cause the avoidance of public spaces, social events and work opportunities, which further worsens quality of life and exacerbates the feelings of depression and isolation.
In light of the intricate interconnection between inflammatory processes, pain, depression and stress in psoriasis, it is imperative to adopt an integrated approach to treatment. Biologic therapies targeting cytokines such as TNF-α, IL-12/23, and IL-17 demonstrate efficacy in reducing inflammation and alleviating both cutaneous and psychological symptoms. A number of studies have reported that patients undergoing treatment with biologics not only experience significant improvements in physical symptoms but also report better mental health outcomes, including reductions in depressive symptoms]. Etanercept and adalimumab significantly improved patients’ Dermatology Life Quality Index (DLQI) scores, showing not contingent effects on the severity of skin symptoms, proving the key role of inflammation in both physical and psychological aspects of psoriasis. Psychological therapies and lifestyle modifications, including regular exercise, healthy diet, correct sleep hygiene behaviours, can lessen the stress-related exacerbations and improve the quality of life in general.
Numerous studies proved that non-pharmacological interventions, such as counselling and anti-stigma initiatives, can significantly reduce depression symptoms and enhance patients’ coping mechanism, which supports the importance of the holistic approach to psoriasis treatment and care [8].
CONCLUSIONS
Psoriasis remains a complex systemic inflammatory condition, which significantly affects many aspects of patients’ lives, not being limited to the skin condition only. Being a continuous cycle of symptoms which tend to intensify each other, such as pain, depression and stress, psoriasis demands a holistic treatment approach. The inflammatory processes affect not only the visual condition of the skin but also mood disorders and joint mobility. Effective treatment should include effective biologic medications to target inflammation, alongside psychological interventions. It is essential to emphasise both physical and psychological well-being of patients suffering from psoriasis, to successfully break the cycle of symptom exacerbations and enhance the overall quality of life.
